About Avicanna

Avicanna has rooted itself as an
innovative biopharmaceutical company
in the medical cannabis space.

Aras Azadian

MBA – Chief Executive Officer

Aras brings with him extensive senior management experience in the biotechnology and financial sectors including his involvement in several successful start-up companies. In addition to his international experience in corporate development, his diverse roles include his previous position as the president of an investment corporation in the cannabis space and former Chief Operating Officer of an oncology company. Aras has a Bachelor of Economics degree from York University in Toronto, and a Master of Business Administration degree from EADA Business School in Barcelona, Spain.

Setu Purohit

JD – President

Setu is a lawyer and entrepreneur with experience in complex corporate and legal strategy, contract negotiations, and litigation. He has been involved in the cannabis industry for several years as an advocate for patients’ rights and advising healthcare professionals, licensed cannabis producers, and other corporate and regulatory stakeholders in Canada and abroad. Setu has received a Bachelor of Commerce degree from the University of Ottawa and Juris Doctorate (JD) degree from the University of Western Ontario. Prior to co-founding Avicanna, Setu operated his own private practice for several years.

Dr. Christine Allen

PhD - Chief Scientific Officer

Dr. Christine Allen is a Professor and the GlaxoSmithKline Chair in Pharmaceutics and Drug Delivery in the Leslie Dan Faculty of Pharmacy at the University of Toronto. Dr. Allen’s research is focused on the design and development of new materials and technologies for the delivery of drugs and contrast agents in addition to Synthesis of new polymer materials for nanotechnology-based drug delivery. Her research has resulted in over one hundred twenty peer-reviewed publications on both lipid and polymer-based drug delivery approaches.

Dave Sohi

CPA, CA, CBV – Chief Financial Officer

Dave is a graduate from Queen’s School of Business and in 2008 received his Chartered Accountant designation. Following three years in audit and tax at RSM Richter LLP, he joined the group’s advisory practice where he worked in mergers and acquisitions focussing on valuations. Following his tenure at RSM Richter LLP, Dave worked at Ernst & Young’s and was a member of their advisory practice. Before becoming Avicanna’s Chief Financial Officer, Dave owned and operated his own financial and accounting consultancy practice.

Arash Moghani

MBA – Chief Technology Officer

Arash brings with him significant management consulting and operational experience across several sectors including banking, technology and healthcare. Previously a management consultant at Deloitte and the Bank of Montreal, Arash lead complex strategy and business transformation projects that enabled successful business outcomes globally. Additionally, Arash has been involved in several start-up companies over the past few years. Arash holds an Honours Bachelor of Arts degree in Digital Enterprise Management from the University of Toronto and a Masters of Business Administration from the Grenoble Graduate School of Business in Grenoble, France.

Lucas Nosiglia

MBA – Chief Agricultural Officer

Lucas is an Executive Vice President of Avicanna, and the President of Avicanna LATAM – a wholly owned subsidiary of Avicanna based in Santa Marta, Colombia. Lucas´ executive experience includes his role as a business development consultant for Sanatorio Guemes in Buenos Aires Argentina, one of the key medical institutions in Latin America. Through a separate role at Deloitte, Lucas has also gained experience in both finance and consulting, which has served him well in developing successful start-up companies in Argentina.. Lucas holds a Master’s degree in Finance from EADA Business School in Barcelona, Spain as well as a Master of Business Administration degree from Pepperdine University in Malibu, California.

Ivana Maric

EVP Marketing

Ivana has significant experience within different disciplines of marketing including advertising, strategy, social media management and brand development across several industries. In her former role as Director of Marketing at Ophiuchus Consulting Group, she was responsible for several brand launches in Canada in addition to managing the marketing efforts of several Toronto based start-up companies. Her specialty includes consumer brands with a primary focus on digital marketing and advertising. Ivana has a Bachelor of Commerce degree in Marketing Management from Ryerson University.

Jose Beltran

PhD – EVP Corporate Development

José has over thirty years of pharmaceutical and health industry experience in Latin America. He has been on the executive management team of Pfizer, Abbott, Aspen and Biotoscana and is an expert in marketing & sales management. He has extensive experience working with diverse cultural environments and in leading multi-functional project teams. He holds degrees in Industrial Engineering and Marketing from University of Los Andes in Colombia and a certificate in Program for Leadership Development (PLD24) from Harvard University.

Janeth Mora

Pharm D – EVP Commercialization

Dr. Mora is an executive within the pharmaceutical industry, with broad and qualified experience in regulatory affairs and marketing across emerging markets. Dr. Mora began her career with the Colombian Regulatory Agency, INVIMA, and then continued in the pharmaceutical industry with Merck & co. She later joined Pfizer Inc. in 1997 where she held different positions of increasing responsibility in regulatory affairs, and then subsequently in marketing for specialty/orphan products. Dr. Mora currently acts as a Strategy and Business Development Advisor for companies in LATAM interested in developing businesses in the region. Janeth also holds degrees in Management, Marketing and Negotiation.

Dr. Hance Clarke

MD, PhD

Dr. Hance Clarke is currently the Director of Pain Services and the Medical Director of the Pain Research Unit at the Toronto General Hospital. He is recognized internationally for his research on novel Transitional Pain Programs, novel Acute Pain Treatment and identifying risk factors associated to opioid use. He is well regarded as one of the top international clinicians researching the efficacy of cannabinoids in pain management. Over the past five years he has authored forty-seven peer reviewed manuscripts.

Dr. Amza Ali

MD, PhD, MBA

Dr. Amza Ali trained in neurology in both the United Kingdom and in the United States. He has received international recognition for his work in the Caribbean related to advancing the care of patients with epilepsy. The development of a sustainability model in his current doctoral program, at the Henley Business School in the United Kingdom, drives his interest in new pharmacological solutions for epilepsy and other neurological conditions. Dr. Ali holds a Master in Business Administration from the Rotman School of Management, University of Toronto. He is a Fellow of the American Epilepsy Society and the President of the Caribbean Epilepsy Society.

Dr. Mauricio Torres-Pradilla

MD, PhD

Dr. Mauricio Torres Pradilla is a Dermatologist with a specialization in pediatric dermatology. He has been involved in research on Atopic Dermatitis, Psoriasis, Epidermolysis Bullosa and Hemangiomas in Europe and South America. Mauricio has several publications on these topics, individually and in collaboration. He is currently the Head of Dermatology at Fundación Universitaria de Ciencias de la Salud in Bogota, Colombia and is a Dermatologist at Debra Colombia, dividing his time among three major teaching hospitals and private practice.

Dr. Carlos Maldonado

MD

Dr. Carlos Enrique Maldonado Muete is a physician, pharmacologist and professor of pharmacology who contributes his experience in biotechnology, pharmacovigilance, clinical studies and knowledge of the medical community and regulatory authorities, as a local and international lecturer. Among other roles, he has participated in medical and regulatory issues related to the approval and commercialization of several new medicines. Dr. Muete has achieved results through his role as a former Medical Director of international pharmaceutical companies and as an external advisor.

Dr. Humberto Reynales

MD, PhD

Originally from Colombia, Dr. Reynales is an MD in Internal Medicine. He holds a PhD in Epidemology from the University of Sao Paulo, Brazil as well as an MBA from Duke University and has completed a Global Clinical Scholars Research Training Program at Harvard Medical School. He has more than 15 years of experience in the pharmaceutical industry with Merck & Co in the area of Clinical Research. Since 2009, he is the founder and Executive Director of CAIMED, a private clinical research organization with operations in four countries in Latin America, and a leader in clinical trials implementation as well as design and conduct of observational studies in several therapeutic areas.

Dr. Alejandro Berlin

MD, MSc

Dr. Berlin trained in Chile, Israel and Canada, and currently works as a staff Clinician-Scientist Radiation Oncologist at the Princess Margaret Cancer Centre. His practice focuses in the characterization of malignancies with MRI and molecular imaging, and original applications of combinatorial approaches using systemic agents, stereotactic and MRI-guided ablative treatments. He is particularly interested in the design of innovative clinical trials, translational oncology, and genomic-based biomarker discovery, conveying his clinical and research expertise towards novel treatments for patients with cancer.

Dr. Frantz Le Devedec

PhD – Senior Vice President R&D

Frantz has over 15 years of experience in academic and industrial R&D projects, including material sciences and drug delivery formulations. He is author of over a dozen research papers and patents. His background is in biochemistry, with a PhD in applied polymer chemistry, and expertise in analytical and pharmaceutical sciences.

Dr. Justin Grant

PhD, MBA – Senior Vice President Clinical Development

Dr. Justin Grant has over fifteen years experience in leading pharmaceutical research in sustained drug release formulations. He held academic appointments at the University of Toronto’s Faculty of Pharmacy and UHN’s Techna Institute for the Advancement of Technology for Health. For over 10 years, he has managed a $50M preclinical cancer research facility (the STTARR Innovation centre) at Princess Margaret Cancer Centre. Justin is currently the Chair of the Scientific Advisory Board for Avicanna.

Dr. Adriana Carrillo

MD, MSc – Senior Vice President Medical Development

Dr. Carillo is a Medical Doctor and has a Master of Epidemiology Degree from Rosario University in Bogota, Colombia. Dr. Carillo has ten years of experience within the fields of Pharmaceuticals and Biotechnologies at Merck Serono, Sanofi Genzyme and Roche where her main focus was on Multiple Sclerosis Disease. She has also experience in implementing clinical trial proposals, launching products across LATAM, developing promotional materials to train sale forces, and interacting with main Key Opinion Leaders of the LATAM Region.

Dr. Satish Asotra

PhD, MBA – Senior Vice President Scientific Affairs

Dr. Satish Asotra holds a PhD in Physiology and a Master of Business Administration from the Ivey School of Business. He has experience in driving development, innovation and process improvement of pharmaceutical and healthcare products. Dr. Asotra has lead teams to obtain regulatory approval of pharmaceutical drug products for the U.S.A., Canada and international markets. Dr. Asotra has also authored over ten patent applications and has published thirty-five scientific papers. He is an expert in directing technology transfer processes supporting commercial manufacturing as well as the launching and liaising of marketing activities.

Dr. Akm Hai

PhD, CChem – Vice President R&D

Dr. Hai has twenty-five years of extensive product development experience, including creating formulations, compound synthesis, and analytical method development. Having completed his PhD at Okayama University in Japan, in addition to his Post-Doctoral Fellowship at North Carolina State University, Dr. Hai has experience developing pharmaceutical grade drugs and related delivery systems at GLP (Good Laboratory Practices) and GMP (Good Manufacturing Practices) level of standards with quality testing using instruments such as GC-FID, HPLC-UV, UV-Vis, FT-IR, and GPC-RI.

Samantha Watt

MSc – Vice President of Scientific Affairs

Samantha’s experience investigating human physiology and cellular biology has allowed her to develop sophisticated laboratory and project management skills that contribute to Avicanna’s competitive edge in the department of Research and Development. More specifically, Samantha has been published on several different occasions and has also lead various conferences and presentations related to plant gene manipulation and cloning. Samantha received a Master of Science degree in from the University of Guelph.

Aras Azadian

MBA – Chief Executive Officer

Aras brings with him extensive senior management experience in the biotechnology and financial sectors including his involvement in several successful start-up companies. In addition to his international experience in corporate development, his diverse roles include his previous position as the president of an investment corporation in the cannabis space and former Chief Operating Officer of an oncology company. Aras has a Bachelor of Economics degree from York University in Toronto, and a Master of Business Administration degree from EADA Business School in Barcelona, Spain.

Setu Purohit

JD – President

Setu is a lawyer and entrepreneur with experience in complex corporate and legal strategy, contract negotiations, and litigation. He has been involved in the cannabis industry for several years as an advocate for patients’ rights and advising healthcare professionals, licensed cannabis producers, and other corporate and regulatory stakeholders in Canada and abroad. Setu has received a Bachelor of Commerce degree from the University of Ottawa and Juris Doctorate (JD) degree from the University of Western Ontario. Prior to co-founding Avicanna, Setu operated his own private practice for several years.

Dr. Chandra Panchal

PHD

Dr. Panchal is the Chief Executive Officer of Axcelon Biopolymers, has authored over seventy scientific papers, holds several patents in oncology, diagnostics, biopolymers and microbiology, and is a Professor in Chemical and Biochemical Engineering at the University of Western Ontario. He currently sits on the board of directors of both an oncology company known as Medicenna Therapeutics (MDNA), and Canadian Oil Recovery and Remediation Inc. (CVR). Dr. Panchal obtained a Master of Science degree in Molecular Biology and a PhD in Biochemical Engineering from the University of Western Ontario.

David White

CA, MBA

David is a director and chair of audit committees of several TSX and NASDAQ companies. He has held a number of senior financial positions with John Labatt Limited, Lawson Marden Group Inc. and Laidlaw Inc. and most recently CEO of TransCare Inc., a medical transportation company and President and CEO of Student Transportation of America, a TSX listed company. Mr. White has been a Canadian Chartered Accountant since 1978 and has an MBA from the University of Toronto.